Reported Earnings • Jul 18
Second quarter 2026 earnings released: EPS: kr3.09 (vs kr1.92 in 2Q 2025) Second quarter 2026 results: EPS: kr3.09 (up from kr1.92 in 2Q 2025). Revenue: kr8.38b (up 1.7% from 2Q 2025). Net income: kr841.0m (up 61% from 2Q 2025). Profit margin: 10.0% (up from 6.4% in 2Q 2025). The increase in margin was primarily driven by lower expenses. Revenue is forecast to grow 4.7% p.a. on average during the next 3 years, compared to a 6.0% growth forecast for the Medical Equipment industry in the United Kingdom. Over the last 3 years on average, earnings per share has remained flat whereas the company’s share price has increased by 3% per year. Announcement • Jun 03
Getinge Launches Vasoview Hemopro 3 Endoscopic Vessel Harvesting System Getinge announced the launch of the Vasoview Hemopro 3 Endoscopic Vessel Harvesting (EVH) System, including the Hemopro 3 Harvesting Tool and dedicated Hemopro 3 Power Supply. The system represents the latest evolution of Getinge's EVH platform, enhancing decades of experience supporting coronary artery bypass grafting (CABG) procedures. Endoscopic vessel harvesting is a minimally invasive technique used to obtain blood vessels, most commonly the saphenous vein or radial artery, for use in CABG surgery. Vessel harvesting plays a critical role in procedural success, as conduit quality and incision-related complications can significantly impact outcomes and recovery. Compared with traditional open harvesting methods, EVH has been associated with reduced wound complications, less postoperative pain, faster recovery, and improved cosmetic results. Getinge has completed an Initial Launch of the Vasoview Hemopro 3 EVH System and has received valuable, positive customer feedback. Getinge has continuously refined EVH technology with a focus on preserving conduit quality while improving the patient and clinician experience. Through close collaboration with vessel harvesting specialists, Getinge has advanced EVH technology in a deliberate, user-driven way, ensuring solutions evolve alongside clinical practice. The Vasoview Hemopro 3 system incorporates targeted enhancements across ergonomics, energy control, visualization, and workflow efficiency, informed by input from more than 100 vessel harvesting specialists worldwide. A redesigned Harvesting Tool features an ergonomic, game-controller-style handle and a soft-touch Activation Toggle that allows activation with minimal force and multiple hand positions, supporting clinician comfort and control throughout the procedure. The system also introduces simplified connectivity through an integrated Harvesting Tool Power Cable, providing a one-click connection to the new Vasoview Hemopro 3 Power Supply and eliminating the need for extension cable sterilization. The dedicated Power Supply is designed to deliver consistent energy and promote efficient cut-and-cautery performance with minimal downtime. Hemopro 3 includes features which support consistent visibility, safety, and workflow efficiency during EVH. Vasoview Hemopro 3 is launching in the U.S., with a training supported rollout available for U.S. customers. Getinge plans a phased expansion outside the U.S., with availability in additional markets to follow based on regulatory approvals and market readiness. Vasoview Hemopro 2 will continue to be available as Getinge rollout availability of Vasoview Hemopro 3. Recent Insider Transactions • May 31
CEO, President & Director recently bought kr4.7m worth of stock On the 29th of May, Mattias Perjos bought around 25k shares on-market at roughly kr188 per share. This transaction amounted to 12% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Mattias has been a buyer over the last 12 months, purchasing a net total of kr7.6m worth in shares. Announcement • Mar 12
Getinge AB (publ) Announces Malin Persson Declines Re-Election as Board Member, Effective April 21, 2026 Getinge AB (publ) at its Annual General Meeting to be held on April 21, 2026, announced Malin Persson has declined re-election as board member. Announcement • Jan 28
Getinge AB (publ), Annual General Meeting, Apr 21, 2026 Getinge AB (publ), Annual General Meeting, Apr 21, 2026. Announcement • Jan 27
Getinge AB (Publ) Proposes Dividend Getinge AB (publ) announced the proposal of dividend per share of SEK 4.75 (4.60). Announcement • Dec 19
Getinge AB Announces Malin Persson Declines Re-Election to the Board Getinge AB announced that Malin Persson, a board member since 2014, has announced that she will not be available for re-election to the board in 2026. Announcement • Oct 21
Getinge AB (Publ) Reaffirms Earnings Guidance for the Year 2025 Getinge AB (publ) reaffirmed earnings guidance for the year 2025. The company remain with expectation for organic net sales growth to be in the range of 2% to 5% and long-term financial target of over 12% EPS growth is also intact despite the headwind from tariffs and currency. Announcement • Jul 02
Getinge AB (publ)(OM:GETI B) dropped from OMX Stockholm 30 Index Getinge AB (publ) has been dropped from the OMX OMX Stockholm 30 Index Announcement • Mar 18
Getinge Introduces Neural Pressure Support for the Servo-U Ventilator System Getinge announces the launch of its latest innovation in ICU ventilation – Neural Pressure Support (NPS) – available for both invasive and non-invasive ventilation. Building on its most personalized ventilation modes, NAVA and NIV NAVA, these two new NPS modes offer clinicians more options to provide personalized ventilation that aims to protect both the lungs and diaphragm. For years, Getinge has been market-driving when it comes to developing first-of-its-kind intensive care ventilation modes. The medtech company is introducing NPS and NIV NPS to widen its neurally controlled ventilation offering. The new Neural Pressure Support modes give clinicians the opportunity to deliver classical pressure support ventilation, enhanced with neural trigger and breath termination in synchrony with diaphragmatic muscle activity. This may be particularly beneficial for complex and challenging ICU patient groups, such as obstructive COPD patients requiring instant synchronization and fast pressurization, and restrictive ARDS patients with stiff lungs and an excessive respiratory drive. Announcement • Jan 29
Getinge AB (publ), Annual General Meeting, Apr 22, 2025 Getinge AB (publ), Annual General Meeting, Apr 22, 2025. Location: halmstad Sweden Announcement • Jan 28
Getinge AB (publ) Provides Organic Sales Guidance for the Year 2025 Getinge AB (publ) provided organic sales guidance for the year 2025. The company have a positive outlook on 2025 and expect organic sales growth of 2%-5% for the full year 2025. Announcement • Nov 28
Getinge AB (Publ) Announces Changes of the Nomination Committee Getinge AB (publ) announced that the composition of Getinge AB (publ)'s Nomination Committee ahead of the 2025 Annual General Meeting has been updated following changed ownership structure in the company. As a consequence, Carnegie Fonder has appointed Simon Blecher as member of the Nomination Committee. This means that Getinge's Nomination Committee ahead of the 2025 Annual General Meeting comprises the company's Chairman, Johan Malmquist, and representatives from the following owners, listed by size: 1. Carl Bennet AB: Carl Bennet 2. Fourth Swedish National Pension Fund: Jannis Kitsakis 3. AMF Pension & Fonder: Dick Bergquist 4. Carnegie Fonder: Simon Blecher 5. Swedbank Robur: Marianne Nilsson. Announcement • Nov 09
Getinge Appoints Alexandra Holland Executive Vice President of Communications, Effective November 11, 2024 Getinge appointed Alexandra Holland as the new Executive Vice President of Communications effective November 11, 2024. Alexandra will become a member of the Getinge Executive Team and lead the development, advancement, and execution of the company's communications and public affairs strategy. Alexandra has dedicated her career to healthcare, including almost 15 years at Johnson & Johnson in the consumer, corporate, and medtech sectors. Most recently, Alexandra served as Vice President, Business and Culture Communications, MedTech, responsible for championing key initiatives to improve and protect reputation, drive business results, advance culture, and deliver value to patients, customers and shareholders. Alexandra Holland will report to Mattias Perjos and be a member of Getinge's executive team. She will be based in the United States and will take office on November 11th. Announcement • Sep 13
Getinge AB (publ) (OM:GETI B) completed the acquisition of Paragonix Technologies, Inc. from Signet Healthcare Partners. Getinge AB (publ) (OM:GETI B) entered into an agreement to acquire Paragonix Technologies, Inc. from Signet Healthcare Partners for approximately $480 million on August 22, 2024. Approximately $477 million, on a cash and debt free basis, for all issued and outstanding shares, of which $253 million is payable in cash on closing. The earn-out payments are expected to be paid between 2024 and 2026 if agreed upon regulatory and financial performance milestones are achieved and may exceed $224 million in aggregate. The initial payout related to the acquisition will be financed through a bridge loan provided by SEB. In 2023, Paragonix Technologies reported revenues of $43.1 million. Upon closing, Paragonix will become a wholly owned subsidiary of Getinge.
The Boards of Directors of both Paragonix and Getinge have approved the transaction. The transaction is subject to subject to antitrust regulations and pending the satisfaction of customary closing conditions. The closing is expected to take place late Q3 or early Q4 2024.
Sheppard, Mullin, Richter & Hampton LLP is acted as legal advisor, Knobbe, Martens, Olson & Bear, LLP is acted as Intellectual Property counsel and UBS Investment Bank is acted as exclusive financial advisor to Paragonix.
Getinge AB (publ) (OM:GETI B) completed the acquisition of Paragonix Technologies, Inc. from Signet Healthcare Partners on September 11, 2024. All conditions for the transaction have now been fulfilled. Announcement • Aug 23
Getinge AB (publ) (OM:GETI B) entered into an agreement to acquire Paragonix Technologies, Inc. from Signet Healthcare Partners for approximately $480 million. Getinge AB (publ) (OM:GETI B) entered into an agreement to acquire Paragonix Technologies, Inc. from Signet Healthcare Partners for approximately $480 million on August 22, 2024. Approximately $477 million, on a cash and debt free basis, for all issued and outstanding shares, of which $253 million is payable in cash on closing. The earn-out payments are expected to be paid between 2024 and 2026 if agreed upon regulatory and financial performance milestones are achieved and may exceed $224 million in aggregate. The initial payout related to the acquisition will be financed through a bridge loan provided by SEB. In 2023, Paragonix Technologies reported revenues of $43.1 million. Upon closing, Paragonix will become a wholly owned subsidiary of Getinge.
The Boards of Directors of both Paragonix and Getinge have approved the transaction. The transaction is subject to subject to antitrust regulations and pending the satisfaction of customary closing conditions. The closing is expected to take place late Q3 or early Q4 2024.
Sheppard, Mullin, Richter & Hampton LLP is acted as legal advisor, Knobbe, Martens, Olson & Bear, LLP is acted as Intellectual Property counsel and UBS Investment Bank is acted as exclusive financial advisor to Paragonix. Announcement • Jul 01
Getinge AB (publ) to Report Q2, 2024 Results on Jul 18, 2024 Getinge AB (publ) announced that they will report Q2, 2024 results at 8:00 AM, Central European Standard Time on Jul 18, 2024 Reported Earnings • Apr 27
First quarter 2024 earnings released: EPS: kr1.69 (vs kr2.15 in 1Q 2023) First quarter 2024 results: EPS: kr1.69 (down from kr2.15 in 1Q 2023). Revenue: kr7.51b (up 5.2% from 1Q 2023). Net income: kr459.0m (down 22% from 1Q 2023). Profit margin: 6.1% (down from 8.2% in 1Q 2023). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 5.2% p.a. on average during the next 3 years, compared to a 6.2% growth forecast for the Medical Equipment industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 18% per year but the company’s share price has only fallen by 7% per year, which means it has not declined as severely as earnings. Announcement • Apr 23
Getinge AB (publ) Declares A Dividend, Payable on 29 April 2024 Getinge AB (publ)'s Annual General Meeting held on 22 April 2024, approved in accordance with the proposal by the Board of Directors and the CEO, the AGM resolved to declare a dividend of SEK 4.40 per share. 24 April 2024 was determined as record date for dividend. The dividend is expected to be distributed by Euroclear Sweden AB starting 29 April 2024. Declared Dividend • Apr 11
Dividend increased to kr4.40 Dividend of kr4.40 is 3.5% higher than last year. Ex-date: 23rd April 2024 Payment date: 29th April 2024 Dividend yield will be 2.0%, which is lower than the industry average of 2.4%. Sustainability & Growth Dividend is covered by both earnings (50% earnings payout ratio) and cash flows (75% cash payout ratio). The dividend has increased over the past 10 years. However, payments have been volatile during that time. EPS is expected to grow by 39% over the next 3 years, which should provide support to the dividend and adequate earnings cover. Announcement • Mar 08
Getinge Takes A Leap Forward in Cardiovascular Surgery with the 510(k) Clearance for Vasoview Hemopro 3 Getinge announced the U.S. Food and Drug Administration's (FDA) 510(k) clearance of the Vasoview Hemopro 3, the latest addition to the medtech company's endoscopic vessel harvesting (EVH) solutions. Designed with customer centricity top of mind, the newcomer is expected to offer enhanced procedural efficiency in healthcare from the upcoming launch. Receiving the FDA 510(k) clearance for Vasoview Hemopro 3 marks a significant milestone for Getinge and underscores the effort to comply with the highest safety and effectiveness standards, emphasizing the medtech company's commitment to advancing medtech. The culmination of extensive market research and advisory boards conducted in partnership with clinicians within the EVH field, Vasoview Hemopro 3 represents collaborative innovation. Feedback from the studies has been central in shaping the product, focusing on improvements that enhance harvester efficiency and patient outcomes. Advancements include enhanced smoke evacuation, regulated energy control, ergonomic game controller style handle, and an integrated cable. Announcement • Jan 23
Getinge Announces CFO Changes Lars Sandström is leaving the position as Getinge's CFO for a new opportunity outside of the company. He will be succeeded by Agneta Palmér, who has been working at Getinge since 2018, most recently in the role of Executive Vice President Operational Services and member of the executive management team. Agneta Palmér most recently served as Executive Vice President Operational Services and prior to that she was Vice President Corporate Control at Getinge. She has previously held similar positions at AB Volvo. The change will take effect at the end of March, when Lars Sandström leaves Getinge. Valuation Update With 7 Day Price Move • Dec 09
Investor sentiment improves as stock rises 19% After last week's 19% share price gain to kr232, the stock trades at a forward P/E ratio of 22x. Average forward P/E is 24x in the Medical Equipment industry in Europe. Total returns to shareholders of 30% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at kr311 per share. Reported Earnings • Oct 24
Third quarter 2023 earnings released Third quarter 2023 results: Revenue: kr7.61b (up 9.6% from 3Q 2022). Net income: kr894.0m (up 12% from 3Q 2022). Profit margin: 12% (in line with 3Q 2022). Revenue is forecast to grow 3.5% p.a. on average during the next 3 years, compared to a 6.3% growth forecast for the Medical Equipment industry in the United Kingdom. Announcement • Oct 12
Getinge AB (publ) (OM:GETI B) acquired Healthmark Industries Company, Inc. for $320 million. Getinge AB (publ) (OM:GETI B) acquired Healthmark Industries Company, Inc. for $320 million on October 11, 2023. The acquisition has been financed through cash on hand and existing credit facilities. The statutorily required waiting period under the Hart-Scott-Rodino Antitrust Improvements Act (HSR) has passed. The transaction is closed and is not subject to further regulatory approvals or waiting periods.Getinge AB (publ) (OM:GETI B) completed the acquisition of Healthmark Industries Company, Inc. on October 11, 2023. Announcement • Sep 20
Getinge AB (Publ) Announces Resignation of Jeanette Hedén Carlsson as Executive Vice President Brand & Communication, Effective December 31, 2023 Getinge announced that Jeanette Hedén Carlsson has decided to resign after 6 years as Executive Vice President, Brand & Communication, and member of the Executive Team. The process to recruit a successor will start immediately. Jeanette Hedén Carlsson will continue in her current role until December 31, 2023. Reported Earnings • Jul 20
Second quarter 2023 earnings released: EPS: kr0.79 (vs kr2.21 in 2Q 2022) Second quarter 2023 results: EPS: kr0.79 (down from kr2.21 in 2Q 2022). Revenue: kr7.18b (up 7.6% from 2Q 2022). Net income: kr214.0m (down 65% from 2Q 2022). Profit margin: 3.0% (down from 9.0% in 2Q 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 2.9% p.a. on average during the next 3 years, compared to a 6.0% growth forecast for the Medical Equipment industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 7% per year whereas the company’s share price has fallen by 5% per year. Announcement • Jul 08
Getinge Receives US FDA 510(K) Clearance for Servo-Air® Lite Getinge announced clearance from the US FDA for Servo-air®? Lite, a wall gas independent non-invasive mechanical ventilator. Servo-air®?lite is Getinge's turbine-driven ventilator for non-invasive ventilation. Like all Servo ventilators, it offers ICU-quality ventilation but is more geared towards spontaneously breathing patients in need of extra breathing support. With its powerful turbine and long-lasting battery backup power, it can also be operated independent of wall gas and is suitable for intrahospital transports. It features embedded workflows, support for High Flow therapy, CO2 monitoring option and tools to support escalation of therapy if needed to. The product is expected to be available for customers in the US from September 2023. New Risk • Jun 21
New minor risk - Dividend sustainability The dividend is not well covered by cash flows. Cash payout ratio: 105% Dividend yield: 2.2% This is considered a minor risk. Dividends are ultimately paid out of the company's available cash reserves. Companies that pay out too much of their cash flow are at risk of having to reduce or cut their dividend in future. If cash flow growth slows or cash flows fall, then there may not be enough cash reserves to maintain the same dividend. Or in extreme cases, companies may opt to take on debt to maintain the dividend. This risk is mitigated by the fact the dividend is covered by earnings, however, cash flows are generally more important. For dividend paying companies, any reduction in the dividend can significantly impact the share price. Currently, the following risks have been identified for the company: Major Risk Shares are highly illiquid. Minor Risk Dividend is not well covered by cash flows (105% cash payout ratio). Valuation Update With 7 Day Price Move • Jun 20
Investor sentiment deteriorates as stock falls 22% After last week's 22% share price decline to kr194, the stock trades at a forward P/E ratio of 18x. Average forward P/E is 32x in the Medical Equipment industry in the United Kingdom. Total returns to shareholders of 13% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at kr309 per share. Buying Opportunity • Jun 10
Now 21% undervalued Over the last 90 days, the stock is up 11%. The fair value is estimated to be kr312, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Earnings per share has grown by 3.0%. For the next 3 years, revenue is forecast to grow by 4.4% per annum. Earnings is also forecast to grow by 11% per annum over the same time period. Announcement • Jun 01
Getinge AB (publ) (OM:GETI B) entered into an agreement to acquire High Purity New England Inc. for approximately $290 million. Getinge AB (publ) (OM:GETI B) entered into an agreement to acquire High Purity New England Inc. for approximately $290 million on May 31, 2023. The consideration comprises of approximately $120 million in cash on closing, on a cash and debt free basis. In addition, a maximum earn out of approximately $170 million can be paid out in 2024 - 2026 if agreed net revenue performance milestones are achieved in 2023 - 2025. The acquisition will be financed through cash at hand and Getinge's net debt to EBITDA ratio is expected to be impacted by 0.3x at the closing of deal. Getinge expects to have fully integrated HPNE by the end of 2024 and anticipates no material integration costs in 2023 - 2024. The acquisition is not expected to have a material impact on Getinge's operating profit and earnings per share in 2023.
The transaction is subject to and conditional upon customary consents, closing and regulatory conditions being fulfilled, including review by the Committee on Foreign Investment in the United States and completion of the statutorily required waiting period under the Hart-Scott-Rodino Antitrust Improvements Act. The transaction is expected to close in Q3 2023. Buying Opportunity • May 17
Now 20% undervalued Over the last 90 days, the stock is up 7.1%. The fair value is estimated to be kr314, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Earnings per share has grown by 3.0%. For the next 3 years, revenue is forecast to grow by 4.3% per annum. Earnings is also forecast to grow by 7.9% per annum over the same time period. Reported Earnings • Apr 28
First quarter 2023 earnings released First quarter 2023 results: Revenue: kr7.14b (up 16% from 1Q 2022). Net income: kr586.0m (up 9.7% from 1Q 2022). Profit margin: 8.2% (down from 8.6% in 1Q 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 4.4% p.a. on average during the next 3 years, compared to a 6.0% growth forecast for the Medical Equipment industry in the United Kingdom. Upcoming Dividend • Apr 20
Upcoming dividend of kr4.25 per share at 1.6% yield Eligible shareholders must have bought the stock before 27 April 2023. Payment date: 04 May 2023. Payout ratio is a comfortable 46% and this is well supported by cash flows. Trailing yield: 1.6%. Lower than top quartile of British dividend payers (5.8%). Lower than average of industry peers (2.4%). Announcement • Feb 03
Getinge Provides Financial Guidance for the First Half, Second Half and Full Year of 2023 Getinge provided financial guidance for the first half, second half and full year of 2023. For 2023 the company expecting a weaker first half of the year as a result of continuing challenging comparative figures for significant parts of Acute Care Therapies and Life Science.Whereas the second half of the year is expected to be stronger. This will result in healthy growth for the company in the second half of the year.Anticipated organic sales growth of 2-5% for the full-year. Reported Earnings • Feb 02
Full year 2022 earnings released: EPS: kr9.15 (vs kr10.90 in FY 2021) Full year 2022 results: EPS: kr9.15 (down from kr10.90 in FY 2021). Revenue: kr28.3b (up 4.6% from FY 2021). Net income: kr2.49b (down 16% from FY 2021). Profit margin: 8.8% (down from 11% in FY 2021). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 5.0% p.a. on average during the next 3 years, compared to a 6.5% growth forecast for the Medical Equipment industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 12% per year whereas the company’s share price has increased by 13% per year. Announcement • Feb 02
Getinge AB (Publ) Proposes Dividend Getinge AB (publ) proposed dividend per share of SEK 4.25 (SEK 4.00). Reported Earnings • Oct 21
Third quarter 2022 earnings released Third quarter 2022 results: Revenue: kr6.94b (up 10% from 3Q 2021). Net income: kr798.0m (up 5.4% from 3Q 2021). Profit margin: 12% (in line with 3Q 2021). Revenue is forecast to grow 5.0% p.a. on average during the next 3 years, compared to a 6.8% growth forecast for the Medical Equipment industry in the United Kingdom. Reported Earnings • Jul 20
Second quarter 2022 earnings released: EPS: kr2.21 (vs kr2.93 in 2Q 2021) Second quarter 2022 results: EPS: kr2.21 (down from kr2.93 in 2Q 2021). Revenue: kr6.67b (up 1.3% from 2Q 2021). Net income: kr603.0m (down 24% from 2Q 2021). Profit margin: 9.0% (down from 12% in 2Q 2021). The decrease in margin was driven by higher expenses. Over the next year, revenue is forecast to grow 8.7%, compared to a 11% growth forecast for the industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 41% per year but the company’s share price has only increased by 20% per year, which means it is significantly lagging earnings growth. Valuation Update With 7 Day Price Move • Jun 23
Investor sentiment deteriorated over the past week After last week's 19% share price decline to kr227, the stock trades at a forward P/E ratio of 18x. Average forward P/E is 28x in the Medical Equipment industry in the United Kingdom. Total returns to shareholders of 65% over the past three years. Valuation Update With 7 Day Price Move • May 03
Investor sentiment deteriorated over the past week After last week's 22% share price decline to kr279, the stock trades at a forward P/E ratio of 21x. Average forward P/E is 29x in the Medical Equipment industry in the United Kingdom. Total returns to shareholders of 115% over the past three years. Recent Insider Transactions • Apr 30
Insider recently bought kr502k worth of stock On the 27th of April, Magnus Lundback bought around 2k shares on-market at roughly kr295 per share. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought kr4.7m more in shares than they have sold in the last 12 months. Board Change • Apr 28
Insufficient new directors There is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 5 experienced directors. 6 highly experienced directors. Independent Director Kristian Samuelsson was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Reported Earnings • Apr 03
Full year 2021 earnings released: EPS: kr10.90 (vs kr11.89 in FY 2020) Full year 2021 results: EPS: kr10.90 (down from kr11.89 in FY 2020). Revenue: kr27.0b (down 9.3% from FY 2020). Net income: kr2.97b (down 8.3% from FY 2020). Profit margin: 11% (in line with FY 2020). Over the next year, revenue is forecast to grow 9.4%, compared to a 12% growth forecast for the industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 77% per year but the company’s share price has only increased by 52% per year, which means it is significantly lagging earnings growth. Board Change • Apr 01
Insufficient new directors There is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 5 experienced directors. 6 highly experienced directors. Independent Director Kristian Samuelsson was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Recent Insider Transactions • Feb 12
President of Acute Care Therapies recently bought kr486k worth of stock On the 10th of February, Jens Viebke bought around 1k shares on-market at roughly kr374 per share. In the last 3 months, there was an even bigger purchase from another insider worth kr571k. Insiders have collectively bought kr4.1m more in shares than they have sold in the last 12 months. Announcement • Jan 30
Getinge AB to Report Q4, 2022 Results on Feb 01, 2023 Getinge AB announced that they will report Q4, 2022 results on Feb 01, 2023 Reported Earnings • Jan 29
Full year 2021 earnings: EPS in line with expectations, revenues disappoint Full year 2021 results: EPS: kr10.90 (down from kr11.89 in FY 2020). Revenue: kr27.0b (down 9.3% from FY 2020). Net income: kr2.97b (down 8.3% from FY 2020). Profit margin: 11% (in line with FY 2020). Revenue missed analyst estimates by 1.2%. Over the next year, revenue is forecast to grow 8.3%, compared to a 14% growth forecast for the industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 77% per year but the company’s share price has only increased by 50% per year, which means it is significantly lagging earnings growth. Buying Opportunity • Jan 15
Now 21% undervalued after recent price drop Over the last 90 days, the stock is down 11%. The fair value is estimated to be kr422, however is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 7.7% per annum over the last 3 years. The company has become profitable over the last 3 years. Recent Insider Transactions • Dec 11
Chief Financial Officer recently bought kr467k worth of stock On the 9th of December, Lars Sandstrom bought around 1k shares on-market at roughly kr389 per share. In the last 3 months, there was an even bigger purchase from another insider worth kr1.9m. This was Lars' only on-market trade for the last 12 months. Recent Insider Transactions • Nov 03
Insider recently bought kr388k worth of stock On the 1st of November, Magnus Lundback bought around 1k shares on-market at roughly kr388 per share. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought kr5.9m more in shares than they have sold in the last 12 months. Reported Earnings • Oct 21
Third quarter 2021 earnings released The company reported a poor third quarter result with weaker earnings, revenues and profit margins. Third quarter 2021 results: Revenue: kr6.31b (down 21% from 3Q 2020). Net income: kr757.0m (down 45% from 3Q 2020). Profit margin: 12% (down from 17% in 3Q 2020). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 105% per year but the company’s share price has only increased by 63% per year, which means it is significantly lagging earnings growth. Reported Earnings • Jul 18
Second quarter 2021 earnings released: EPS kr2.93 (vs kr1.81 in 2Q 2020) The company reported a decent second quarter result with improved earnings and profit margins, although revenues were weaker. Second quarter 2021 results: Revenue: kr6.59b (down 5.5% from 2Q 2020). Net income: kr798.0m (up 62% from 2Q 2020). Profit margin: 12% (up from 7.1% in 2Q 2020). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 90% per year but the company’s share price has only increased by 56% per year, which means it is significantly lagging earnings growth. Recent Insider Transactions • Apr 30
Chief Commercial Officer recently bought kr272k worth of stock On the 21st of April, Carsten Blecker bought around 1k shares on-market at roughly kr272 per share. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought kr5.6m more in shares than they have sold in the last 12 months. Recent Insider Transactions • Apr 27
Chief Commercial Officer recently bought kr272k worth of stock On the 21st of April, Carsten Blecker bought around 1k shares on-market at roughly kr272 per share. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought kr5.6m more in shares than they have sold in the last 12 months. Recent Insider Transactions • Apr 26
Chief Commercial Officer recently bought kr272k worth of stock On the 21st of April, Carsten Blecker bought around 1k shares on-market at roughly kr272 per share. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought kr5.6m more in shares than they have sold in the last 12 months. Executive Departure • Apr 24
Director has left the company On the 20th of April, Johan Stern's tenure in the role of Director ended. We don't have any record of a personal shareholding under Johan's name. Johan is the only executive to leave the company over the last 12 months. Reported Earnings • Apr 22
First quarter 2021 earnings released: EPS kr2.36 (vs kr0.99 in 1Q 2020) The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2021 results: Revenue: kr6.17b (up 2.3% from 1Q 2020). Net income: kr644.0m (up 138% from 1Q 2020). Profit margin: 10% (up from 4.5% in 1Q 2020). The increase in margin was primarily driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 84% per year but the company’s share price has only increased by 41% per year, which means it is significantly lagging earnings growth. Upcoming Dividend • Apr 14
Upcoming dividend of kr3.00 per share Eligible shareholders must have bought the stock before 21 April 2021. Payment date: 27 April 2021. Trailing yield: 1.1%. Lower than top quartile of British dividend payers (4.2%). Lower than average of industry peers (1.9%). Reported Earnings • Apr 02
Full year 2020 earnings released: EPS kr11.89 (vs kr4.49 in FY 2019) The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: kr29.8b (up 12% from FY 2019). Net income: kr3.24b (up 165% from FY 2019). Profit margin: 11% (up from 4.6% in FY 2019). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 66% per year but the company’s share price has only increased by 36% per year, which means it is significantly lagging earnings growth. Is New 90 Day High Low • Feb 13
New 90-day high: kr233 The company is up 28% from its price of kr182 on 13 November 2020. The British market is up 6.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Medical Equipment industry, which is up 6.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is kr390 per share.